THRAP3: A Potential Drug Target and Biomarker (G9967)

Target Name: THRAP3

NCBI ID: G9967

THRAP3

THRAP3: A Potential Drug Target and Biomarker

THRAP3, short for triple negative transforming gene 3, is a gene that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique feature is its triple negative expression, which means it is not expressed in normal tissues and is mainly expressed in immune cells.

THRAP3 is a member of the TGF-β pathway, a well-known signaling pathway that regulates cell growth, differentiation, and inflammation. The TGF-β pathway has been implicated in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Therefore , targeting the TGF-β pathway is a promising strategy for developing new treatments for these diseases.

Studies have shown that THRAP3 is involved in the regulation of immune cell function and has been associated with the development of various autoimmune diseases, such as rheumatoid arthritis, lupus, and multiple sclerosis. In addition, THRAP3 has also been shown to be involved in cancer development and progression. For example, THRAP3 has been shown to be expressed in various types of cancer, including breast, ovarian, and colorectal cancer.

Furthermore, recent studies have also shown that THRAP3 can be used as a biomarker for cancer diagnosis and treatment. For example, researchers have found that THRAP3 expression is significantly associated with cancer poor prognosis in patients with colorectal cancer. In addition, THRAP3 has also been shown to be expressed in brain metastatic cancer cells, which may have a poor prognosis.

In addition to its potential as a drug target and biomarker, THRAP3 also has potential as a therapeutic agent. For example, researchers have shown that inhibiting THRAP3 can protect cancer cells from apoptosis, which is a mechanism by which cells respond to stress and try to eliminate themselves to prevent tissue damage. Therefore, THRAP3 may be a useful target for cancer chemotherapy.

In conclusion, THRAP3 is a gene that has potential as a drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its triple negative expression and involvement in the TGF-β pathway make it an attractive target for researchers to investigate further. Further studies are needed to determine the full extent of THRAP3's involvement in various diseases and its potential as a therapeutic agent.

Protein Name: Thyroid Hormone Receptor Associated Protein 3

Functions: Involved in pre-mRNA splicing. Remains associated with spliced mRNA after splicing which probably involves interactions with the exon junction complex (EJC). Can trigger mRNA decay which seems to be independent of nonsense-mediated decay involving premature stop codons (PTC) recognition. May be involved in nuclear mRNA decay. Involved in regulation of signal-induced alternative splicing. During splicing of PTPRC/CD45 is proposed to sequester phosphorylated SFPQ from PTPRC/CD45 pre-mRNA in resting T-cells. Involved in cyclin-D1/CCND1 mRNA stability probably by acting as component of the SNARP complex which associates with both the 3'end of the CCND1 gene and its mRNA. Involved in response to DNA damage. Is excluced from DNA damage sites in a manner that parallels transcription inhibition; the function may involve the SNARP complex. Initially thought to play a role in transcriptional coactivation through its association with the TRAP complex; however, it is not regarded as a stable Mediator complex subunit. Cooperatively with HELZ2, enhances the transcriptional activation mediated by PPARG, maybe through the stabilization of the PPARG binding to DNA in presence of ligand. May play a role in the terminal stage of adipocyte differentiation. Plays a role in the positive regulation of the circadian clock. Acts as a coactivator of the CLOCK-BMAL1 heterodimer and promotes its transcriptional activator activity and binding to circadian target genes (PubMed:24043798)

The "THRAP3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about THRAP3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets